SEAPORT THERAPEUTICS, INC. COMMON STOCK
NASDAQ: SPTX (Seaport Therapeutics, Inc.)
最近更新时间: 昨天, 11:30AM18.05
-0.27 (-1.47%)
AIStockmoo 评分
| 价值 43% | 0.0 |
| 负债低。短期流动性充足。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 盈利趋势 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 | NA |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 趋势强度 参考 | NA |
| 技术形态 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 29% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 持仓情绪 参考 | NA |
| 新闻情绪 参考 | NA |
| 聪明钱 29% | 0.0 |
| 内部人士近期净卖出。 参考 | |
| 机构在最新13F申报中净+1.10%的股份:47家增持,18家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+18.4%,回补天数17.4天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 没有支柱有明确读数,评分不变。 | |
| 不计入评分 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。 参考 | |
| 短期动能下降。 参考 | |
| 股价接近阻力位。 参考 | |
| 最终评分 | 0.00 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Seaport Therapeutics, Inc. | - | - |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| SPTX | 966 M | - | - | 2.47 | 0.0 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
|
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 34.97% |
| 机构持股比例 | 72.09% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Trv Gp Vi, Llc | 30 Sep 2026 | 2,061,222 |
| Canada Pension Plan Investment Board | 30 Sep 2026 | 1,975,791 |
| Foresite Capital Management Vi Llc | 30 Sep 2026 | 1,779,521 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ZOHAR DAPHNE | - | 21.97 | -100,000 | -2,197,000 |
| 累积净数量 | -100,000 | |||
| 累积净值 ($) | -2,197,000 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 21.97 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| ZOHAR DAPHNE | 职员 | 10 Nov 2026 | 处理 (-) | 100,000 | 21.97 | 2,197,000 |
机构
机构持股比例: 71.26%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 47 | 2,485,976 |
| 减持 | 18 | 1,817,822 |
| 新建仓 | 26 | 298,039 |
| 清仓 | 6 | 372,738 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 3,733,388 | 17.4 |
| 15 Oct 2026 | 3,718,915 | 17.9 |
| 30 Sep 2026 | 3,649,879 | 8.9 |
| 15 Sep 2026 | 3,148,881 | 20.7 |
| 31 Aug 2026 | 3,152,409 | 26.0 |
| 14 Aug 2026 | 3,012,877 | 25.1 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 05 Nov 2026 | Yahoo Finance |
How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91%
The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
| 02 Nov 2026 | Yahoo Finance |
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BOSTON, November 02, 2026--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress… |
| 28 Oct 2026 | Yahoo Finance |
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
BOSTON, October 28, 2026--Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference… |
| 25 Oct 2026 | Yahoo Finance |
Is Seaport Therapeutics (SPTX) Overvalued Based On Book Value?
Seaport Therapeutics has just logged a sharp move in its share price over the past week, which naturally raises the question of whether the latest market enthusiasm lines up with what its book value supports. For anyone watching Seaport Therapeutics, the key issue now is how much of the current… |
| 25 Oct 2026 | Yahoo Finance |
Seaport Therapeutics (SPTX) Looks Cheap After Its Cash Runway Narrative Took Center Stage
Seaport Therapeutics (SPTX) has drawn fresh attention after recent trading left the shares at $20.61, with short term moves showing a mix of gains and pullbacks over the past week and month. Recent trading in Seaport Therapeutics points to choppy but generally improving sentiment, with a 7 day… |
| 09 Oct 2026 | Yahoo Finance |
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress… |
| 07 Oct 2026 | Yahoo Finance |
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON, October 07, 2026--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance… |
| 07 Oct 2026 | Yahoo Finance |
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON, October 07, 2026--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance… |
| 22 Sep 2026 | Yahoo Finance |
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year. |
| 22 Sep 2026 | Yahoo Finance |
PureTech Health H1 Earnings Call Highlights
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit… |
| 14 Sep 2026 | Yahoo Finance |
Seaport Therapeutics to Participate in September Investor Conferences
BOSTON, September 14, 2026--Seaport Therapeutics, Inc. (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional… |
| 09 Sep 2026 | Yahoo Finance |
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON, September 09, 2026--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers… |
| 31 Aug 2026 | Yahoo Finance |
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
BOSTON, August 31, 2026--Seaport Therapeutics to present at Citi’s 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference… |
| 26 Aug 2026 | Yahoo Finance |
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls… |
| 显示更多 | ||
近期信号 K线形态与EMA交叉
AI 技术分析
投资组合